Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

RecruitingOBSERVATIONAL
Enrollment

400,000

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

December 30, 2030

Study Completion Date

December 30, 2032

Conditions
Pancreatic CancerIntraductal Papillary Mucinous NeoplasmHigh-grade Pancreatic Intraepithelial NeoplasiaPDAC - Pancreatic Ductal AdenocarcinomaMucinous Cystic Neoplasm
Interventions
DIAGNOSTIC_TEST

Diagnostic Evaluation for Positive AI Findings

MDT will review positive AI findings (including PDAC, pancreatic precursor lesions and benign lesion) cases to determine next steps: (1) Suspected PDAC and pancreatic precursor lesions are referred for hospital examination with diagnostic results collected; (2) Benign lesion cases receive personalized monitoring until endpoint events or study end; (3) Cases with positive AI findings but MDT-confirmed normal pancreatic issues receive at least one year of follow-up. If any abnormal results arise, management will transition to either plan (1) or (2).

Trial Locations (5)

200072

RECRUITING

Meinian Onehealth Healthcare Holdings Co., Ltd, Shanghai

200126

RECRUITING

Ruici Medical Examination Institution, Shanghai

200433

RECRUITING

Changhai Hospital, Shanghai

314000

RECRUITING

Jiaxing University Affiliated Second Hospital, Jiaxing

315100

RECRUITING

Ningbo University Affiliated People's Hospital, Ningbo

All Listed Sponsors
collaborator

Ningbo University Affiliated People's Hospital

UNKNOWN

collaborator

Jiaxing University Affiliated Second Hospital

UNKNOWN

collaborator

Meinian Onehealth Healthcare Holdings Co., Ltd

UNKNOWN

collaborator

Ruici Medical Examination Institution

UNKNOWN

lead

Changhai Hospital

OTHER

NCT07117045 - Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer | Biotech Hunter | Biotech Hunter